Exelixis (EXEL) vs Kymera Therapeutics (KYMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Exelixis (EXEL) over the past year, gaining 94.2% versus a gain of 52.7%. Over five years, EXEL leads with a +170.5% price change compared with +91.1% for KYMR. Exelixis is the larger company by market cap ($14.98 billion vs $9.23 billion), about 1.6 times the size.
Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | KYMR |
|---|---|---|
| Share price | $60.45 | $112.21 |
| Market cap | $14.98B | $9.23B |
| 1-day change | +2.42% | +2.66% |
| YTD return | +34.66% | +40.47% |
| 1-year return | +52.74% | +94.17% |
| 5-year return | +170.49% | +91.08% |
| P/E ratio (TTM) | 19.07 | — |
| Forward P/E | 14.25 | — |
| EPS (TTM) | $3.17 | $-3.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | $39.21M |
| Revenue growth (YoY) | +6.98% | -16.70% |
| Net income (latest FY) | $782.57M | $-311.35M |
| Gross margin | 96.39% | 0.00% |
| Operating margin | 37.59% | -891.07% |
| Net margin | 33.73% | -794.04% |
| 52-week high | $61.14 | $130.05 |
| 52-week low | $33.76 | $55.26 |
| Distance from 52-week high | -1.13% | -13.72% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -9.79% | +24.16% |
| Average volume | 2.34M | 705.63K |
| Shares outstanding | 247.78M | 82.26M |
| Employees | 1,077 | 273 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed EXEL by 41.4 percentage points over the past year.
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- Exelixis grew revenue faster in its latest fiscal year (+6.98% vs -16.70%).
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
EXEL vs KYMR FAQ
Which is bigger, Exelixis or Kymera Therapeutics?
Exelixis (EXEL) is larger, with a market capitalization of $14.98B compared with $9.23B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, EXEL or KYMR?
KYMR returned +94.17% over the past 12 months, compared with +52.74% for EXEL (price return, excluding dividends). Past performance does not predict future results.
Are Exelixis and Kymera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.